We have done this before
DRIVE’s leadership has extensive experience in the biotechnology and pharmaceutical industries with proven track records in discovering and developing successful and valuable antiviral drugs.
WE HAVE THE RESOURCES
Emory University has invested over $20M in foundational funding to build a world class infrastructure for developing drugs for viral diseases of global concern. DRIVE has access to these resources to accelerate its drug development process. View Lab
WE ARE A NOT-FOR-PROFIT THAT THINKS LIKE A FOR PROFIT
Our formal relationship with Emory University enables us to have the best of both worlds — access to the intellectual and physical assets of a major research university while still maintaining the independence and focus of a biotechnology company. Thus, DRIVE can quickly and efficiently move therapeutics down the development continuum. Our non-profit status and commercial approach allows us to spin-off companies to address commercial needs in the developed world and also receive funding to address the unmet needs of biodefense and the developing world.
We are focused
We are applying what we have learned from our past successes with treatments for HIV, HBV, HCV, and herpes viruses to develop novel treatments for viruses that are currently untreatable.
